 We believe that Acadia Pharmaceuticals stock, a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades around 17 levels currently and it is, in fact, down 64 from its pre-Covid high of around 47 in February 2020. 